FDA Approves Two New Weight Loss Drugs Foundayo and Zepbound for Obesity

The FDA has approved two significant new medications for chronic weight management, marking important advances in obesity treatment options. Foundayo (orforglipron) received approval on April 2, 2026, while Zepbound (tirzepatide) injection was also approved within the past two weeks, expanding the therapeutic landscape for weight management.

Both medications target adults with obesity (BMI ≥30 kg/m²) or those who are overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. Qualifying conditions include high blood pressure, type 2 diabetes, and high cholesterol. The approvals require these drugs to be used as adjuncts to lifestyle modifications, specifically reduced-calorie diets and increased physical activity.

These approvals are particularly significant given the obesity epidemic affecting over 40% of American adults. Tirzepatide, the active ingredient in Zepbound, has shown promising results in clinical trials as a dual GIP/GLP-1 receptor agonist. Orforglipron represents a newer approach to weight management pharmacotherapy.

For clinicians, these approvals provide additional evidence-based tools for treating obesity and its associated metabolic complications. The medications may help patients achieve meaningful weight loss when lifestyle interventions alone prove insufficient. However, long-term safety data and real-world effectiveness will continue to be monitored post-approval.

Patients considering these treatments should discuss potential benefits and risks with their healthcare providers, as individual responses may vary and side effects are possible with any new medication.